Figure 1
![Figure 1. Overall survival according to cytogenetic risk in patients above 60 years. Data derived from the HOVON/SAKK study (HOVON 43) investigating the value of high-dose daunorubicin show OS according to cytogenetic risk in patients >60 years.3 CBF, core-binding factors; CN, normal karyotype (including –Y,–Y); CA rest, other cytogenetic abnormalities; Unfav, MK-, complex cytogenetic abnormalities (at least 3 unrelated cytogenetic abnormalities), monosomies, or partial deletions of chromosome 5 or 7 (del[5q], del[7q], −5, −7), abnormalities of the long arm of chromosome 3 (q21;q26), t(6;9) (p23;q34), t(9;22)(q34;q11.2), or abnormalities involving the long arm of chromosome 11 (11q23); MK, monosomal karyotype; N, numbers; F, failures (death).](https://ash.silverchair-cdn.com/ash/content_public/journal/blood/125/5/10.1182_blood-2014-08-551499/4/767f1.jpeg?Expires=1735500536&Signature=w425BJbElSrbD5jqlH77i7M4Ag1igQNbf3HwLECPEXMsJaCpij-IK6v6dFuR4x1s5Xuf1-PJpVrEVacqeY-iP1OrUeXgz36Xqkm2Ci3eH6rhFRBWRdZzVDzGXiqbZubUdnZoudcToLkJaJ8aVHjpfWjzD6mXpp7T4aRVVUIUQ9DD44fcLZlsNEq4Jb9NcZCzF391B0YNQSXu8SZ0VL6qs8Q28mAZLiHoa7w-TrjhAwFMDx0FYKbA84GcHtUXTsoSaCoPDqi3lzLg1oOdk7dy9WzrluHGRx7p7MAG7SWP5gSqrTsbfyPjLOeJFxBwXoC4QKnR19YiUoOg~i4ftSbkeQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
Overall survival according to cytogenetic risk in patients above 60 years. Data derived from the HOVON/SAKK study (HOVON 43) investigating the value of high-dose daunorubicin show OS according to cytogenetic risk in patients >60 years.3 CBF, core-binding factors; CN, normal karyotype (including –Y,–Y); CA rest, other cytogenetic abnormalities; Unfav, MK-, complex cytogenetic abnormalities (at least 3 unrelated cytogenetic abnormalities), monosomies, or partial deletions of chromosome 5 or 7 (del[5q], del[7q], −5, −7), abnormalities of the long arm of chromosome 3 (q21;q26), t(6;9) (p23;q34), t(9;22)(q34;q11.2), or abnormalities involving the long arm of chromosome 11 (11q23); MK, monosomal karyotype; N, numbers; F, failures (death).
